Annexon, Inc.

ANNX

US03589W1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.7 ^USD	+2.40%		+3.07%	+3.52%

Apr. 01	JPMorgan Raises Price Target on Annexon to $13 From $11, Maintains Overweight Rating	MT
Mar. 27	Wells Fargo Adjusts Price Target on Annexon to $12 From $11, Maintains Overweight Rating	MT

Annexon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 26, 2024 at 04:11 pm EDT

Annexon, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 134.24 million compared to USD 141.95 million a year ago. Basic loss per share from continuing operations was USD 1.77 compared to USD 2.6 a year ago.

Latest news about Annexon, Inc.

JPMorgan Raises Price Target on Annexon to $13 From $11, Maintains Overweight Rating	Apr. 01	MT
Wells Fargo Adjusts Price Target on Annexon to $12 From $11, Maintains Overweight Rating	Mar. 27	MT
Annexon Q4 Loss Narrows	Mar. 26	MT
Annexon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Annexon, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 26	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
North American Morning Briefing : Inflation Worries Continue to Weigh on Mood	Mar. 15	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Transcript : Annexon, Inc. - Special Call	Mar. 01
JPMorgan Upgrades Annexon to Overweight From Neutral, Price Target is $11	Mar. 01	MT
Annexon Insider Bought Shares Worth $1,008,000, According to a Recent SEC Filing	Dec. 28	MT
North American Morning Briefing : Dow Futures Fall -2-	Dec. 22	DJ
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	Dec. 21	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	Dec. 21	MT
Sector Update: Health Care	Dec. 21	MT
Annexon Shares Jump on Stock Offering Pricing, BofA Upgrade	Dec. 21	MT
BofA Securities Upgrades Annexon to Buy From Neutral	Dec. 21	MT
Exchange-Traded Funds, Equity Futures Recover Pre-Bell Thursday to Continue Rate Cut-Fueled Rally	Dec. 21	MT
BofA Securities Upgrades Annexon to Buy From Neutral, Adjusts Price Target to $6 From $4	Dec. 21	MT
Annexon Prices $125 Million Share Offering	Dec. 21	MT
Annexon, Inc. Outlines Global Registrational Program for Anx007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint	Dec. 20	CI
Annexon Reports Phase 1 Results for ANX1502, Its Oral Small Molecule Inhibitor of the Classical Complement Pathway	Dec. 20	CI
Annexon, Inc.(NasdaqGS:ANNX) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Annexon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
North American Morning Briefing : Traders Await -2-	Nov. 09	DJ

Chart Annexon, Inc.

Duration

Period

More charts

Company Profile

Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. It has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.

Sector

Pharmaceuticals

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.7 USD

Average target price

15.17 USD

Spread / Average Target

+222.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ANNEXON, INC.	+3.52%	428M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B

Biopharmaceuticals

Annexon, Inc.

Equities

ANNX

US03589W1027

Pharmaceuticals

Annexon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

Latest news about Annexon, Inc.

Chart Annexon, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals